Further evidence of the protective effects of ECs in atherosclerosis comes from the demonstration that CB1 inhibition in ApoE−/− mice is able to promote the down-regulation of vascular angiotensin II type 1 receptor (AT1), which is responsible for NOXs activation when stimulated by angiotensin II [201]. This evidence concerns the gene APOE and atherosclerosis.